Juno Therapeutics Overview
- Year Founded
-
2013
- Status
-
Acquired/Merged
- Employees
-
663
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$10.4B
Juno Therapeutics General Information
Description
Developer of cell-based novel immunotherapies intended to change the way cancer and other serious diseases are treated. The company is engaged in developing autologous cellular biologics as an answer to overcoming tumor evasion as well as programming T cells to recognize and attack cancer cells, enabling medical professionals to treat various types of cancer.
Contact Information
Website
www.junotherapeutics.comCorporate Office
- 400 Dexter Avenue North
- Suite 1200
- Seattle, WA 98109
- United States
Corporate Office
- 400 Dexter Avenue North
- Suite 1200
- Seattle, WA 98109
- United States
Juno Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Merger/Acquisition | 06-Mar-2018 | $10.4B | Completed | Generating Revenue | ||
| 7. Secondary Transaction - Open Market | 01-Sep-2017 | Completed | Generating Revenue | |||
| 6. 2PO | 14-Sep-2015 | Completed | Generating Revenue | |||
| 5. PIPE | 29-Jun-2015 | Completed | Clinical Trials - Phase 2 | |||
| 4. IPO | 19-Dec-2014 | Completed | Clinical Trials - Phase 2 | |||
| 3. Early Stage VC (Series B) | 01-Aug-2014 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC (Series A) | 24-Apr-2014 | $176M | $183M | Completed | Clinical Trials - Phase 1 | |
| 1. Early Stage VC (Series A1) | 26-Dec-2013 | $6.67M | $6.67M | Completed | Product Development |
Juno Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A2 | ||||||||
| Series A1 | 9,000,000 | $0.000100 | 8% | $1 | $1 | 1x | $1 | 2.27% |
| Series A | 87,722,673 | $0.000100 | 8% | $1 | $1 | 1x | $1 | 22.15% |
Juno Therapeutics Comparisons
Industry
Financing
Details
Juno Therapeutics Competitors (39)
One of Juno Therapeutics’s 39 competitors is Allogene Therapeutics, a Formerly VC-backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Allogene Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| Alaunos Therapeutics | Formerly VC-backed | Houston, TX | ||||
| NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
| Gadeta | Formerly VC-backed | Utrecht, Netherlands |
Juno Therapeutics Patents
Juno Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240285762-A1 | Cell therapy for treating systemic autoimmune diseases | Pending | 28-Feb-2023 | ||
| US-20240226298-A1 | Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof | Pending | 13-Dec-2022 | ||
| US-20240041929-A1 | Chimeric antigen receptors specific for gprc5d and bcma | Pending | 05-Aug-2022 | ||
| AU-2023223404-A1 | Proteinase 3 (pr3) chimeric autoantibody receptor t cells and related methods and uses | Pending | 22-Feb-2022 | ||
| EP-4482519-A1 | Proteinase 3 (pr3) chimeric autoantibody receptor t cells and related methods and uses | Pending | 22-Feb-2022 | A61K40/11 |
Juno Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Juno Therapeutics Former Investors (19)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ARCH Venture Partners | Venture Capital | Minority | ||
| Alaska Permanent Fund | Sovereign Wealth Fund | Minority | ||
| BB Biotech | Asset Manager | Minority | ||
| Bezos Expeditions | Family Office | Minority | ||
| Biomark Capital | PE/Buyout | Minority |
Juno Therapeutics Investments & Acquisitions (10)
Juno Therapeutics’s most recent deal was a Early Stage VC with JW Therapeutics for . The deal was made on 03-Jun-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| JW Therapeutics | 03-Jun-2020 | Early Stage VC | Biotechnology | ||
| JW Therapeutics | 20-Nov-2019 | Early Stage VC | Biotechnology | ||
| JW Therapeutics | 09-May-2019 | Early Stage VC | Biotechnology | ||
| JW Therapeutics | 24-May-2018 | Early Stage VC | Biotechnology | ||
| RedoxTherapies | 14-Jul-2016 | Merger/Acquisition | Pharmaceuticals |
Juno Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Juno Therapeutics FAQs
-
When was Juno Therapeutics founded?
Juno Therapeutics was founded in 2013.
-
Where is Juno Therapeutics headquartered?
Juno Therapeutics is headquartered in Seattle, WA.
-
What is the size of Juno Therapeutics?
Juno Therapeutics has 663 total employees.
-
What industry is Juno Therapeutics in?
Juno Therapeutics’s primary industry is Biotechnology.
-
Is Juno Therapeutics a private or public company?
Juno Therapeutics is a Private company.
-
What is the current valuation of Juno Therapeutics?
The current valuation of Juno Therapeutics is .
-
What is Juno Therapeutics’s current revenue?
The current revenue for Juno Therapeutics is .
-
How much funding has Juno Therapeutics raised over time?
Juno Therapeutics has raised $1.56B.
-
Who are Juno Therapeutics’s investors?
ARCH Venture Partners, Alaska Permanent Fund, BB Biotech, Bezos Expeditions, and Biomark Capital are 5 of 19 investors who have invested in Juno Therapeutics.
-
Who are Juno Therapeutics’s competitors?
Allogene Therapeutics, Kite Pharma, Alaunos Therapeutics, NexImmune, and Gadeta are some of the 39 competitors of Juno Therapeutics.
-
When was Juno Therapeutics acquired?
Juno Therapeutics was acquired on 06-Mar-2018.
-
Who acquired Juno Therapeutics?
Juno Therapeutics was acquired by Celgene.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
